[go: up one dir, main page]

EA202092489A1 - СЕЛЕКТИВНЫЙ СТИМУЛЯТОР Treg RUR20kD-IL-2 И РОДСТВЕННЫЕ КОМПОЗИЦИИ - Google Patents

СЕЛЕКТИВНЫЙ СТИМУЛЯТОР Treg RUR20kD-IL-2 И РОДСТВЕННЫЕ КОМПОЗИЦИИ

Info

Publication number
EA202092489A1
EA202092489A1 EA202092489A EA202092489A EA202092489A1 EA 202092489 A1 EA202092489 A1 EA 202092489A1 EA 202092489 A EA202092489 A EA 202092489A EA 202092489 A EA202092489 A EA 202092489A EA 202092489 A1 EA202092489 A1 EA 202092489A1
Authority
EA
Eurasian Patent Office
Prior art keywords
rur20kd
treg
related compositions
selective
compositions
Prior art date
Application number
EA202092489A
Other languages
English (en)
Inventor
Питер Бенедикт Кирк
Джон Л Ланговски
Джонатан Залевский
Original Assignee
Нектар Терапьютикс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67002369&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA202092489(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Нектар Терапьютикс filed Critical Нектар Терапьютикс
Publication of EA202092489A1 publication Critical patent/EA202092489A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Данное изобретение предусматривает композиции селективных стимуляторов Treg, включая RUR20kD-IL-2 и родственные композиции, и способы применения таких композиций, например, для лечения аутоиммунных заболеваний и/или других состояний, поддающихся лечению, которые эффективно обеспечивают селективного увеличение количества и активации регуляторных T-клеток по сравнению с эффекторными T-клетками.
EA202092489A 2018-05-21 2019-05-20 СЕЛЕКТИВНЫЙ СТИМУЛЯТОР Treg RUR20kD-IL-2 И РОДСТВЕННЫЕ КОМПОЗИЦИИ EA202092489A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862674244P 2018-05-21 2018-05-21
PCT/US2019/033100 WO2019226538A1 (en) 2018-05-21 2019-05-20 SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONS

Publications (1)

Publication Number Publication Date
EA202092489A1 true EA202092489A1 (ru) 2021-03-16

Family

ID=67002369

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092489A EA202092489A1 (ru) 2018-05-21 2019-05-20 СЕЛЕКТИВНЫЙ СТИМУЛЯТОР Treg RUR20kD-IL-2 И РОДСТВЕННЫЕ КОМПОЗИЦИИ

Country Status (21)

Country Link
US (1) US20210205413A1 (ru)
EP (1) EP3796940A1 (ru)
JP (3) JP7235772B2 (ru)
KR (2) KR102706554B1 (ru)
CN (2) CN112399859B (ru)
AU (3) AU2019274409B2 (ru)
BR (1) BR112020021564A2 (ru)
CA (1) CA3100204A1 (ru)
CL (1) CL2020003008A1 (ru)
CO (1) CO2020014510A2 (ru)
CR (1) CR20200546A (ru)
DO (1) DOP2020000212A (ru)
EA (1) EA202092489A1 (ru)
EC (1) ECSP20074392A (ru)
IL (2) IL312646A (ru)
JO (1) JOP20200290A1 (ru)
MX (1) MX2024012807A (ru)
PE (1) PE20211307A1 (ru)
PH (1) PH12020551976A1 (ru)
SG (1) SG11202011242SA (ru)
WO (1) WO2019226538A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220140514A (ko) 2020-01-10 2022-10-18 브라이트 피크 테라퓨틱스 아게 변형된 il-2 폴리펩타이드 및 그의 용도
CN113121670B (zh) * 2020-01-15 2022-11-22 天津键凯科技有限公司 二取代peg化白细胞介素2及其制备方法、应用
US20230102464A1 (en) * 2020-01-15 2023-03-30 Jenkem Technology Co., Ltd. (Tianjin) Method for preparing pegylated biomolecule with controllable binding sites
JP2021143142A (ja) * 2020-03-11 2021-09-24 花王株式会社 制御性ｔ細胞誘導剤
US20230272001A1 (en) * 2020-05-22 2023-08-31 Merck Sharp & Dohme Llc Novel processes for preparing conjugates of the il-2 protein
TW202228784A (zh) 2020-09-23 2022-08-01 奧地利商艾柏力維亞生技有限公司 用以於一患者中螯合非預期的抗ｐｅｇ抗體的化合物
WO2022109477A1 (en) * 2020-11-23 2022-05-27 University Of Florida Research Foundation, Incorporated Use of insulin-like growth factors with gamma-chain cytokines to induce homeostatic proliferation of lymphocytes
MX2024007345A (es) 2021-12-14 2024-09-30 Nektar Therapeutics Pautas posologicas para el estimulador de treg selectivo rur20kd-il-2 y composiciones relacionadas.
CN116212040B (zh) * 2023-02-14 2025-11-28 河北菲尼斯生物技术有限公司 一种作为Treg靶向调节剂的PEG修饰IL-2的组合物及其制备方法和用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401756A (en) 1981-04-14 1983-08-30 Immunex Corporation Process for preparing human interleukin 2
US4569790A (en) 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5153310A (en) 1989-02-28 1992-10-06 Du Pont Merck Pharmaceutical Company Il-2 analogs containing n-linked glycosylation sites
US5635597A (en) 1994-05-27 1997-06-03 Affymax Technologies, N.V. Peptides that bind IL-2 receptors
US6168785B1 (en) 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
FR2826365B1 (fr) 2001-06-20 2003-09-26 Oreal Compositions cosmetiques photoprotectrices contenant des derives amides, sulfonamides ou carbamates aromatiques d'acrylonitrile et nouveaux derives amides, sulfonamides ou carbamates d'acrylonitrile
HUE043911T2 (hu) 2003-05-23 2019-09-30 Nektar Therapeutics Két PEG láncot tartalmazó PEG származékok
US7569215B2 (en) 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
US7567215B1 (en) 2007-10-23 2009-07-28 The United States Of America As Represented By The Secretary Of The Navy Portable and inflatable antenna device
KR20200070407A (ko) * 2010-11-12 2020-06-17 넥타르 테라퓨틱스 Ｉｌ-2 부분 및 중합체의 접합체
MX384095B (es) 2011-03-11 2025-03-14 Hopitaux Paris Assist Publique Uso de dosis bajas de il-2 para tratar trastornos inflamatorios o relacionados con la autoinmunidad.
WO2017156720A1 (zh) 2016-03-16 2017-09-21 谢彦晖 糖皮质激素联合聚乙二醇修饰的白介素2治疗呼吸道疾病

Also Published As

Publication number Publication date
EP3796940A1 (en) 2021-03-31
KR102706554B1 (ko) 2024-09-12
AU2019274409B2 (en) 2022-07-14
AU2025200920A1 (en) 2025-03-13
MX2024012807A (es) 2024-11-08
CA3100204A1 (en) 2019-11-28
AU2022246440B2 (en) 2024-11-14
KR20240137713A (ko) 2024-09-20
JP2024116272A (ja) 2024-08-27
PE20211307A1 (es) 2021-07-20
CN112399859B (zh) 2024-11-29
CN120131983A (zh) 2025-06-13
JP2023052053A (ja) 2023-04-11
PH12020551976A1 (en) 2021-09-13
WO2019226538A1 (en) 2019-11-28
CL2020003008A1 (es) 2021-07-30
CO2020014510A2 (es) 2021-03-08
AU2022246440A1 (en) 2022-11-03
IL278528A (ru) 2021-01-31
JP7235772B2 (ja) 2023-03-08
ECSP20074392A (es) 2021-03-31
CR20200546A (es) 2021-05-18
JP2021523922A (ja) 2021-09-09
DOP2020000212A (es) 2021-03-15
BR112020021564A2 (pt) 2021-03-02
US20210205413A1 (en) 2021-07-08
KR20210002577A (ko) 2021-01-08
JP7801991B2 (ja) 2026-01-19
IL278528B2 (en) 2024-10-01
AU2019274409A1 (en) 2020-11-12
JOP20200290A1 (ar) 2020-11-15
SG11202011242SA (en) 2020-12-30
IL312646A (en) 2024-07-01
IL278528B1 (en) 2024-06-01
CN112399859A (zh) 2021-02-23

Similar Documents

Publication Publication Date Title
EA202092489A1 (ru) СЕЛЕКТИВНЫЙ СТИМУЛЯТОР Treg RUR20kD-IL-2 И РОДСТВЕННЫЕ КОМПОЗИЦИИ
EA201992610A1 (ru) Экспансия -t-клеток, композиции и способы их применения
EA202091484A1 (ru) 4-азаиндольные соединения
EA202091480A1 (ru) Аминоиндольные соединения, пригодные в качестве ингибиторов tlr
EA202091809A1 (ru) Агонистические антитела против pd-1 и их применение
MX2022004101A (es) Composiciones de oligonucleotidos y metodos de uso de las mismas.
EA202091508A1 (ru) 6-азаиндольные соединения
EA202091479A1 (ru) Арил- и гетероарилзамещенные индольные соединения
EA202091477A1 (ru) Замещенные соединения простых индольных эфиров
EA201890047A1 (ru) Композиции, содержащие бактериальные штаммы
EA201391755A1 (ru) Анти-kir антитела для лечения воспалительных заболеваний
EA202190073A1 (ru) Композиции и способы лечения видов гемоглобинопатии и талассемии
EA201890161A1 (ru) Терапевтические композиции, комбинации и способы применения
EA202092086A1 (ru) Ингибиторы аргиназы
MX2020014031A (es) Proteinas heterodimericas y usos de las mismas.
EP4628094A3 (en) BAFF-R ANTIBODIES AND THEIR USES
MD4685B1 (ru) Метод лечения состояний, связанных с MASP-2-зависимой активацией комплемента
EA202190094A1 (ru) Антитела против cd40 для применения в лечении аутоиммунного заболевания
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
EA201792561A1 (ru) Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
EA201892500A1 (ru) Применение фракции лигнина в качестве антифитопатогенного агента и содержащие ее антифитопатогенные композиции
EA201892475A1 (ru) Оксабороловые сложные эфиры, их применение
EA202092748A1 (ru) Модуляторы экспрессии apol1
EA201891664A1 (ru) Составы/композиции, содержащие ингибитор btk
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения